Roflumilast
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Roflumilast
Roflumilast is a pre-clinical stage product being developed by AstraZeneca for COPD. The current trial status is completed. This product is registered under clinical trial identifier NCT03381573. Target conditions include COPD.
What happened to similar drugs?
20 of 20 similar drugs in COPD were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (16)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03381573 | Pre-clinical | Completed |
| NCT02068456 | Pre-clinical | Completed |
| NCT01354782 | Phase 1 | Completed |
| NCT01140542 | Phase 2 | Completed |
| NCT00246935 | Phase 3 | Completed |
| NCT00246922 | Phase 3 | Completed |
| NCT00242294 | Phase 2/3 | Completed |
| NCT00108823 | Phase 3 | Completed |
| NCT00242307 | Phase 2/3 | Completed |
| NCT00163475 | Phase 3 | Completed |
| NCT00076076 | Phase 3 | Completed |
| NCT00076089 | Phase 3 | Completed |
| NCT00073177 | Phase 3 | Completed |
| NCT00062582 | Phase 3 | Completed |
| NCT00163527 | Phase 3 | Completed |
| NCT00430729 | Phase 3 | Completed |
Competing Products
20 competing products in COPD